<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082467</url>
  </required_header>
  <id_info>
    <org_study_id>NMRR-19-3798-52441</org_study_id>
    <nct_id>NCT05082467</nct_id>
  </id_info>
  <brief_title>Prolonged Cardiac ECG Patch Versus Conventional Holter For Detecting Atrial Fibrillation After Cerebral Ischemic Event</brief_title>
  <acronym>PROVE-AF</acronym>
  <official_title>Prolonged Cardiac Patch Ambulatory Electrocardiogram Versus Conventional Holter Recording For Detection of Atrial Fibrillation After Cerebral Ischemic Event: A Comparative Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarawak General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sarawak Heart Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Malaysia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sarawak General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the diagnostic yield of water-resistant, wireless 7-day&#xD;
      cardiac ECG patch versus conventional 24-hour Holter recording in detecting paroxysmal atrial&#xD;
      fibrillation in patients admitted with acute ischemic stroke or transient ischemic attack of&#xD;
      undetermined etiology after completion of a standard clinical stroke workup.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cohort study with a paired comparison between a cardiac ECG patch and conventional&#xD;
      Holter system to detect atrial fibrillation in patients with acute ischemic stroke or&#xD;
      transient ischemic attack of undetermined etiology. An estimated total of 320 adult patients&#xD;
      will be enrolled in this study. Each eligible patient will receive simultaneously a&#xD;
      conventional 24h Holter monitoring and a 7d cardiac ECG patch monitoring.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To determine the diagnostic yield of a cardiac ECG patch compared to conventional Holter&#xD;
      monitor for detecting occult paroxysmal atrial fibrillation (AF) within 24 hours in patients&#xD;
      admitted with acute ischemic stroke or transient ischemic attack (TIA) of undetermined&#xD;
      etiology after completion of a standard clinical stroke work-up.&#xD;
&#xD;
      Secondary objective(s):&#xD;
&#xD;
        -  To determine efficacy of prolonged 7-day ambulatory ECG monitoring (using cardiac ECG&#xD;
           patch) compared to conventional 24-hour ambulatory ECG monitoring (using conventional&#xD;
           Holter) strategies in detecting paroxysmal AF.&#xD;
&#xD;
        -  To determine if a strategy of a prolonged 7-day ambulatory ECG monitoring results in a&#xD;
           change in clinical practice, i.e., more patients are anticoagulated.&#xD;
&#xD;
        -  To assess the time to the first detection of AF within the first 7 days of monitoring.&#xD;
&#xD;
      Exploratory objective(s):&#xD;
&#xD;
        -  To identify predictors of occult AF based on clinical, neuroimaging, echocardiography,&#xD;
           and ECG features.&#xD;
&#xD;
        -  To assess feasibility and cost-effectiveness of 7-day cardiac ECG patch monitoring for&#xD;
           detecting occult paroxysmal AF.&#xD;
&#xD;
      SCREENING:&#xD;
&#xD;
        -  Written informed consent obtained from patient or guardian&#xD;
&#xD;
        -  Inclusion/Exclusion criteria.&#xD;
&#xD;
        -  Social demographics, Risk factors, Comorbidities, Admission Brain CT/MRI,Stroke status&#xD;
           including date and time of index event, date and time of admission, admission modified&#xD;
           Rankin scale/NIHSS Score [Data extracted from patient records].&#xD;
&#xD;
        -  12-lead ECG, Transthoracic Echocardiogram&#xD;
&#xD;
      Eligible patients will be enrolled in the study and proceed with a baseline assessment.&#xD;
&#xD;
      BASELINE ASSESSMENT:&#xD;
&#xD;
        -  Concomitant medication, Oxfordshire classification of stroke and CHA2DS2VAS Score [Data&#xD;
           extracted from patient records].&#xD;
&#xD;
        -  Anthropometric measurements and vital signs assessments&#xD;
&#xD;
        -  24h Holter and 7d Cardiac ECG patch monitoring&#xD;
&#xD;
      FOLLOW UP VISITS:&#xD;
&#xD;
      Follow-up visits will occur at 3 months and 1 year for the efficacy and outcomes for the&#xD;
      duration of the study. There will be a total of 2 visits.The investigator/study team will&#xD;
      perform the following procedures at each visit where applicable:&#xD;
&#xD;
        -  Clinical examination (NIHSS Score assessment)&#xD;
&#xD;
        -  Review concomitant medications&#xD;
&#xD;
        -  AE/SAE assessment and monitoring&#xD;
&#xD;
        -  Outcomes assessment&#xD;
&#xD;
        -  Health outcome interview with EQ-5D Questionnaire&#xD;
&#xD;
        -  TOAST Classification (at 1 year follow up visit)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2021</start_date>
  <completion_date type="Anticipated">January 11, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of newly diagnosed AF or atrial flutter within 24 hours of monitoring with cardiac ECG patch compared to conventional Holter.</measure>
    <time_frame>24 hours</time_frame>
    <description>Detection of newly diagnosed AF or atrial flutter within 24 hours of monitoring with cardiac ECG patch compared to conventional Holter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of AF or atrial flutter within 7 days of monitoring.</measure>
    <time_frame>7 days</time_frame>
    <description>Detection of one or more episodes of AF or atrial flutter as assessed after 7 days of Holter monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of stroke patients anticoagulated during follow-up.</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients prescribed with OAC as assessed at 3 month follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stroke recurrent, major adverse bleeding events and detection of AF outside the study protocol.</measure>
    <time_frame>1 year</time_frame>
    <description>One year rate of recurrent ischemic stroke or TIA, hemorrhagic stroke, major adverse bleeding events and detection of AF outside the study protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first detection of AF or atrial flutter.</measure>
    <time_frame>7 days</time_frame>
    <description>Time to first detection of AF or atrial flutter within 7 days of Holter monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Outcomes.</measure>
    <time_frame>1 year</time_frame>
    <description>Health outcome as evaluated by Eq-5D Questionnaire.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Predictors of occult AF.</measure>
    <time_frame>1 month</time_frame>
    <description>To identify predictors of occult AF based on clinical, neuroimaging, echocardiography and Holter monitoring results.</description>
  </other_outcome>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients who are admitted with acute ischemic stroke or transient ischemic attack&#xD;
        (TIA) of undetermined etiology after completion of a standard clinical stroke work-up will&#xD;
        be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Diagnosis of acute ischemic stroke or transient ischemic attack (TIA) (WHO definition)&#xD;
             of undetermined etiology made by neurologist within 7 days after the index event. The&#xD;
             event must be either:&#xD;
&#xD;
               -  an ischemic stroke confirmed by neuroimaging; or&#xD;
&#xD;
               -  a TIA, defined as involving a focal unilateral motor deficit, speech/language&#xD;
                  deficit or hemianopia, with symptom duration &lt;24 hours (note: amaurosis fugax/&#xD;
                  transient monocular blindness, pure sensory spells, isolated vertigo spells, etc.&#xD;
                  do not qualify for enrolment given the potential for misdiagnosis of such&#xD;
                  events).&#xD;
&#xD;
          3. No AF detected in baseline 12-lead ECG on admission.&#xD;
&#xD;
          4. The following diagnostic test have already been completed as part of clinical routine&#xD;
             post-stroke/TIA:&#xD;
&#xD;
               -  Brain imaging with CT or MRI,&#xD;
&#xD;
               -  Transthoracic echocardiography to congenital heart disease and endocarditis.&#xD;
&#xD;
          5. Recurrent stroke/TIA is inclusionary as long as patient meets inclusion/exclusion&#xD;
             criteria for study enrolment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Stroke of unknown time of symptom onset.&#xD;
&#xD;
          2. Modified Rankin Scale ≥5 on index admission.&#xD;
&#xD;
          3. Previous documented history of primary intracerebral bleeding.&#xD;
&#xD;
          4. Previous documented history of AF or atrial flutter (a remote history of transient AF&#xD;
             during perioperative period is not exclusionary).&#xD;
&#xD;
          5. Skin allergies, conditions, or sensitivities to cardiac patch.&#xD;
&#xD;
          6. Exclusively retinal stroke or retinal TIA event.&#xD;
&#xD;
          7. Pre-existing indication for anticoagulation (eg. History of mechanical heart valve&#xD;
             replacement, deep vein thrombosis).&#xD;
&#xD;
          8. Pre-existing contraindication for permanent anticoagulation (eg. hypocoagulable&#xD;
             state).&#xD;
&#xD;
          9. Echocardiographic findings of congenital heart disease and endocarditis.&#xD;
&#xD;
         10. Indicated for pacemaker, implantable cardiac defibrillator (ICD), CRT device, or an&#xD;
             implantable hemodynamic monitoring system.&#xD;
&#xD;
         11. Intravenous drug users (IVDUs).&#xD;
&#xD;
         12. Life expectancy &lt; 1 year for reasons other than stroke (eg. Metastatic cancer&#xD;
             disease).&#xD;
&#xD;
         13. Concomitant participation in other clinical trials involving investigational&#xD;
             medications.&#xD;
&#xD;
         14. Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Hui Ping Foo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sarawak General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Hui Ping Foo, MD</last_name>
    <phone>+60168680633</phone>
    <email>dianafoo.crc@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rose Hui Chin Jong, BSc</last_name>
    <phone>+60108167913</phone>
    <email>genieros3jong@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Hui Ping Foo, MD</last_name>
      <phone>+60168680633</phone>
      <email>dianafoo.crc@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rose Hui Chin Jong, BSc</last_name>
      <phone>+6082276820</phone>
      <email>genieros3jong@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Diana Hui Ping Foo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sarawak General Hospital</investigator_affiliation>
    <investigator_full_name>Diana Hui Ping Foo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Cardiac ECG Patch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The final decision is depending on the agreement among the co-investigators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

